BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 10675407)

  • 1. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women.
    Petter A; Heim K; Guger M; Ciresa-Kö Nig A; Christensen N; Sarcletti M; Wieland U; Pfister H; Zangerle R; Höpfl R
    J Gen Virol; 2000 Mar; 81(Pt 3):701-8. PubMed ID: 10675407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.
    Viscidi RP; Ahdieh-Grant L; Schneider MF; Clayman B; Massad LS; Anastos KM; Burk RD; Minkoff H; Palefsky J; Levine A; Strickler H
    J Infect Dis; 2003 Dec; 188(12):1834-44. PubMed ID: 14673762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.
    Sasagawa T; Inoue M; Lehtinen M; Zhang W; Gschmeissner SE; Hajibagheri MA; Finch J; Crawford L
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):403-10. PubMed ID: 8807204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.
    Viscidi RP; Ahdieh-Grant L; Clayman B; Fox K; Massad LS; Cu-Uvin S; Shah KV; Anastos KM; Squires KE; Duerr A; Jamieson DJ; Burk RD; Klein RS; Minkoff H; Palefsky J; Strickler H; Schuman P; Piessens E; Miotti P
    J Infect Dis; 2003 Jan; 187(2):194-205. PubMed ID: 12552444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study.
    Höpfl R; Petter A; Thaler P; Sarcletti M; Widschwendter A; Zangerle R
    BMC Infect Dis; 2003 Apr; 3():6. PubMed ID: 12723991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) prevalence and HPV antibodies in serum and cervical secretions.
    Marais DJ; Vardas E; Ramjee G; Allan B; Kay P; Rose RC; Williamson AL
    J Infect Dis; 2000 Oct; 182(4):1239-42. PubMed ID: 10979925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 seroconversion promotes rapid changes in cervical human papillomavirus (HPV) prevalence and HPV-16 antibodies in female sex workers.
    Marais DJ; Carrara H; Ramjee G; Kay P; Williamson AL
    J Med Virol; 2009 Feb; 81(2):203-10. PubMed ID: 19107974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus infection in women infected with the human immunodeficiency virus.
    Sun XW; Kuhn L; Ellerbrock TV; Chiasson MA; Bush TJ; Wright TC
    N Engl J Med; 1997 Nov; 337(19):1343-9. PubMed ID: 9358128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of immunoglobulin IgA and IgG against human papilloma virus.
    Gonçalves AK; Machado PR; de Souza LC; Costa AP; Gimenes F; Consolaro ML; Crispim JO; Eleutério J; Giraldo PC
    Viral Immunol; 2014 Nov; 27(9):471-7. PubMed ID: 25191973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
    Kirnbauer R; Hubbert NL; Wheeler CM; Becker TM; Lowy DR; Schiller JT
    J Natl Cancer Inst; 1994 Apr; 86(7):494-9. PubMed ID: 8133532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.
    Bontkes HJ; de Gruijl TD; Walboomers JM; Schiller JT; Dillner J; Helmerhorst TJ; Verheijen RH; Scheper RJ; Meijer CJ
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():409-417. PubMed ID: 10073701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
    Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns.
    Heim K; Hudelist G; Geier A; Szedenik H; Christensen ND; Concin N; Bergant A; Volgger B; Czerwenka K; Höpfl R
    Reprod Sci; 2007 Dec; 14(8):806-14. PubMed ID: 18089599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.
    Studentsov YY; Ho GY; Marks MA; Bierman R; Burk RD
    J Clin Microbiol; 2003 Jul; 41(7):2827-34. PubMed ID: 12843008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Human papillomavirus and human immunodeficiency virus infections as risk factors for cervix cancer in women prisoners].
    de Sanjosé S; Valls I; Paz Cañadas M; Lloveras B; Quintana MJ; Shah KV; Bosch FX
    Med Clin (Barc); 2000 Jun; 115(3):81-4. PubMed ID: 10965480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Specific serologic studies with a novel authentic HPV antigen (virus-like particles) for HPV-6 antibodies in gynecologic patient samples].
    Heim K; Christensen ND; Höpfl R; Wartusch B; Zeimet A; Larcher C; Ruth N; Bergant A; Pirschner G; Dierich MP
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():25-31. PubMed ID: 8672922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.
    Carter JJ; Madeleine MM; Shera K; Schwartz SM; Cushing-Haugen KL; Wipf GC; Porter P; Daling JR; McDougall JK; Galloway DA
    Cancer Res; 2001 Mar; 61(5):1934-40. PubMed ID: 11280749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.
    Nonnenmacher B; Kruger Kjaer S; Svare EI; Scott JD; Hubbert NL; van den Brule AJ; Kirnbauer R; Walboomers JM; Lowy DR; Schiller JT
    Int J Cancer; 1996 Dec; 68(6):704-9. PubMed ID: 8980170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand.
    Sukvirach S; Smith JS; Tunsakul S; Muñoz N; Kesararat V; Opasatian O; Chichareon S; Kaenploy V; Ashley R; Meijer CJ; Snijders PJ; Coursaget P; Franceschi S; Herrero R
    J Infect Dis; 2003 Apr; 187(8):1246-56. PubMed ID: 12696004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.
    Sasagawa T; Rose RC; Azar KK; Sakai A; Inoue M
    Int J Cancer; 2003 Apr; 104(3):328-35. PubMed ID: 12569556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.